BEIJING — Biocytogen Pharmaceuticals has signed a global licensing agreement with BeOne Medicines to provide multiple fully human antibodies for use in drug development, the companies announced.
The agreement builds on a previous partnership in which BeOne licensed access to Biocytogen’s RenMice® platform, a proprietary technology used to generate fully human antibodies. The new deal grants BeOne broader rights to specific antibody candidates, expanding the collaboration between the two firms in the oncology space.
Biocytogen will receive an upfront payment, along with potential development and regulatory milestone payments, commercial milestone payments, and tiered royalties based on future sales of any licensed therapies.
“These antibodies were discovered using our RenMice® platform, and we’re excited to see them move closer to clinical development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This agreement strengthens our partnership with BeOne Medicines and reinforces our shared goal of delivering innovative therapies to patients worldwide.”
BeOne Medicines is focused on developing treatments for cancer and other serious diseases. The licensed antibodies will be used to support its global drug development pipeline.
